avotaciclib
Term · Oncology and biomedicine · MLC-T-ONC-011826
An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.
| Identifier | MLC-T-ONC-011826 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | CDK1 inhibitor BEY1107 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011826",
"term": "avotaciclib",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.",
"synonyms": [
"CDK1 inhibitor BEY1107"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/avotaciclib/"
}
Record 3,182 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.